Year Founded
2020
Ownership
Private
Employees
~50
Stage
Preclinical
Modalities
Small molecule

xFOREST Therapeutics General Information

Developing RNA-targeting small molecules using proprietary FOREST platform for parallel analysis of RNA structures

Contact Information

Website
Primary Industry
Biotech
Corporate Office
Kyoto,
Japan

Drug Pipeline

No pipeline data available

For full access to xFOREST Therapeutics's pipeline data

Book a demo

Key Partnerships

Kyowa Kirin, Takeda

Need more data on over 80,000 life science companies, including over 1200 biotechs?

Book a demo

xFOREST Therapeutics Funding

No funding data available

Early Stage VC (Series A)04-Jun-2020$38MCompletedPhase 1
Seed Round12-Feb-2019$8.5MCompletedStartup

Interested in comprehensive profile data?

We'll help you find what you need

Learn more
To view xFOREST Therapeutics's complete valuation and funding history, request access »

xFOREST Therapeutics Investors

ANRI (Japanese venture capital firm)
Investor Type: Venture Capital
Holding: Minority
Takeda
Investor Type: Venture Capital
Holding: Minority